4. Materials and Methods
KARMS was established in 2023 for the surveillance of AMR in patients with UTIs, and is an internet-based, prospective, multicenter, and national observational survey. KARMS is endorsed by KAUTII and carried out through the website (https://uti.karms.kr/main-page, accessed from 1 January 2023) with the cooperation of medical centers throughout Korea. In 2023, a total of 31 hospitals (including 8 private clinics) participated in KARMS. The participating hospitals were in five administrative provinces (Seoul, Gyeonggi, Chungcheong, Jeolla, and Gyeongsang).
4.2. Data Collection and Study Design
Thirty-five urologists participated in the present study by inputting data for patients with UTIs into the website. Nationality, age, sex, outpatient or inpatient, association (community-acquired, healthcare-associated, hospital-acquired), uncomplicated or complicated, classification of UTI (cystitis, pyelonephritis, catheter-associated UTI, acute prostatitis, chronic prostatitis, urosepsis, or asymptomatic bacteriuria), and recurrence or non-recurrence were investigated. For women, menopausal status was also investigated. Uncomplicated cystitis was defined as acute, sporadic, or recurrent cystitis limited to non-pregnant women with no known relevant anatomic and functional abnormalities within the urinary tract or comorbidities [4,5]. In addition, the clinical and laboratory criteria for patients with UC were defined as (1) the presence of microbes by urine culture (>103 colony forming units/mL); (2) clinical symptoms such as dysuria, urgency, frequency, and feeling of incomplete bladder emptying; and (3) results of urinalysis (white blood cell count >5 cells/high power field). Recurrent UTIs were defined as recurrences of uncomplicated and/or complicated UTIs with a frequency of at least three UTIs per year or two UTIs in the last 6 months [8].
Among the entire UTI data from the KARMS database, any female patient aged ≥18 years diagnosed with clinical UC and microbiologically proven E. coli between January 2023 and December 2023 was included in the present study. Hence, the data for patients with UC and microbiologically proven E. coli between January 2023 and December 2023 were retrieved and analyzed. Patient with age < 18 years, mixed or negative growths in urine culture, complicated cystitis, and other UTIs (pyelonephritis, catheter-associated UTI, prostatitis, urosepsis, or asymptomatic bacteriuria) were excluded from the present study.
4.3. Antimicrobial Susceptibility Testing
All patients in the present study had a urine culture and isolated uropathogenic E. coli. ESBL positivity and antimicrobial susceptibility tests were performed in the local laboratories according to the microbial standards of each institute. In detail, the VITEK® 2 (bioMérieux, Inc., Durham, NC, USA) system was used to perform antimicrobial susceptibility and confirmation assays. For the Vitek 2 system, briefly, a selected colony from the sample was subcultured onto a nutrient medium to produce a fresh colony. After an 18–24 h incubation, this colony was mixed into 3.0 mL of sterile saline (0.45% NaCl), with turbidity adjusted to match the 0.5~0.63 McFarland standard. The prepared suspension, along with an AST card, was then placed in the cassette holder to initiate automated susceptibility testing. Minimum inhibitory concentrations (MICs) of each antibiotic were measured by the agar dilution method according to the recommendations of the CLSI [36]. Antimicrobial susceptibility was interpreted as S (susceptible), I (intermediate), or R (resistant), according to the breakpoints by CLSI recommendations [37,38]. The results of the antimicrobial susceptibility testing were obtained according to each antimicrobial agent: amikacin, amoxicillin/clavulanate, cefazolin, cefepime, cefotaxime, cefoxitin, ceftazidime, ciprofloxacin, ertapenem, fosfomycin, gentamycin, imipenem, levofloxacin, meropenem, nitrofurantoin, piperacillin/tazobactam, and trimethoprim/sulfamethoxazole.
4.4. Statistical Analyses
Statistical analyses were performed using STATA version 16.1 software (StataCorp; College Station, TX, USA). Descriptive analyses were performed to assess patient demographics. Continuous variables are presented as means and standard deviations, and categoric variables are presented as frequencies (%). ESBL positivity, fluoroquinolone resistance, and resistance to third-generation cephalosporins were compared according to clinical factors (hospital region, hospital type, menopause status, and recurrence of infection) using Pearson’s two-sided test and Fisher’s exact test. A logistic regression test was performed to identify clinical factors associated with ESBL positivity and fluoroquinolone resistance. A p value < 0.05 was considered statistically significant.
4.5. Ethics Statement
The study protocol was reviewed and approved by the institutional review board of Chonnam National University Hospital (approval number CNUH-2024-085). This study was performed in accordance with the principles of the Declaration of Helsinki and the Ethical Guidelines for Clinical Studies.
CC BY 4.0. "Antimicrobial Resistance of Escherichia coli for Uncomplicated Cystitis: Korean Antimicrobial Resistance Monitoring System" by Yu SH, Jung SI, Lee SJ et al., Antibiotics (Basel, Switzerland) (2024). https://doi.org/10.3390/antibiotics13111075. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Peer-reviewed and open access; full text from PubMed Central (PMC11591001). Headings and layout adapted for reading; figures and tables are in the original.